Company Description
BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases.
The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development.
Its products in development programs include AG10 and BBP-265, a small molecule stabilizer of transthyretin, or TTR that is in Phase 3 clinical trial for the treatment of TTR amyloidosis-cardiomyopathy, or ATTR-CM; BBP-831, a small molecule selective FGFR1-3 inhibitor, which is Phase 2 clinical trial to treat achondroplasia in pediatric patients; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.
The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 2 proof-of-concept clinical trial for Autosomal Dominant Hypocalcemia Type 1, or ADH1; and BBP-711 for the treatment of hyperoxaluria, as well as patients suffering from recurrent kidney stones.
In addition, it engages in developing products for Mendelian, oncology, and gene therapy diseases.
BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and The Regents of the University of California; Leidos Biomedical Research, Inc.
The company was founded in 2015 and is headquartered in Palo Alto, California.
Country | United States |
IPO Date | Jun 27, 2019 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 550 |
CEO | Dr. Neil Kumar Ph.D. |
Contact Details
Address: 421 Kipling Street Palo Alto, California United States | |
Website | https://www.bridgebio.com |
Stock Details
Ticker Symbol | BBIO |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001743881 |
CUSIP Number | 10806X102 |
ISIN Number | US10806X1028 |
Employer ID | 00-0000000 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Dr. Eric Michael David J.D., M.D., Ph.D. | Chief Executive Officer of Gene Therapy |
Dr. Neil Kumar Ph.D. | Co-Founder, Chief Executive Officer & Director |
Dr. Brian C. Stephenson C.F.A., Ph.D. | Chief Financial Officer & Secretary |
Dr. Thomas Trimarchi Ph.D. | President & Chief Operating Officer |
Dr. Charles J. Homcy M.D. | Co-Founder, Chairman of Pharmaceuticals & Independent Lead Director |
Dr. Frank P. McCormick Ph.D. | Co-Founder, Chairman of Oncology & Director |
Dr. Richard H. Scheller Ph.D. | Chairman of Research & Development |
Dr. Uma Sinha Ph.D. | Chief Scientific Officer |
Eli M. Wallace Ph.D. | Chief Scientific Officer of Oncology |
Grace Rauh | Vice President of Communications |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Dec 12, 2024 | 4 | Filing |
Dec 12, 2024 | 4 | Filing |
Dec 12, 2024 | 4 | Filing |
Nov 25, 2024 | 8-K | Current Report |
Nov 20, 2024 | 4 | Filing |
Nov 20, 2024 | 4 | Filing |
Nov 19, 2024 | 4 | Filing |
Nov 19, 2024 | 4 | Filing |
Nov 19, 2024 | 4 | Filing |
Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |